IQVIA

Market Reflection Report

Oct 2023

10th November

© 2023. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States,
the European Union, and various other countries.
 IPM Overview
TSA SSA
Growth %%

80 60
60 2020-21
40
40 2021-22
20
20 2022-23
0 0
-20 -20
Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct

TSA IPM Trends (Value Rs. 211,575 Crs) – MAT Oct'23 SSA IPM Trends (Value Rs. 178,786 Crs) – MAT Oct'23

+17%
11% +16%
11%
MAT
211,575 MAT
Month 178,786
189,836 Month
178,997 160,925
151,725
152,201
130,236

14,310 15,779 16,297 18,986 12,227 13,369 13,848 16,089

2020 2021 2022 2023 2020 2021 2022 2023

• TSA valued at Rs. 211,575 Cr with growth of 11% as of MAT Oct'23 and Rs 18,986 Cr for Oct'23 month with growth of 17%
• SSA valued at Rs. 178,786 Cr with growth of 11% as of MAT Oct'23 and Rs 16,089 Cr for Oct'23 month with growth of 16%

IQVIA TSA & SSA Dataset Oct'23 1

 Except Derma and Ophthal, all therapies exhibited double digit
growth rate while AI followed by VMN posted highest growth
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)

15 13 24 20 17
IPM 18,986 4 12 10 5 7 6 9
IPM
52 51
16 23 26 9 12 23
ANTI-INFECTIVES 2,487 -2 -1 -5 -2 AI
15 12 17 13 12 13
11 9 9 11 9 8
CARDIAC 2,203 CARDIAC

13 24 15 18
GASTRO 1,913 11 6 7 6 4 7 8 11
GASTRO
56 50
16 21 30 16
RESPIRATORY 1,717 10 -5 -4 9
-7 -6 RESPI
10 13 9 10
7 7 9 5 6 6
ANTI DIABETIC 1,598 4 ADB
5
16 16 26 22 15 17
0 12 6 7 5 10
PAIN 1,537 PAIN
15 17 19
11 12 8 7
7 5 7 7 VMN
VMN 1,474 1
13 11 12 11
6 7 6 8 8 6 3 8
DERMA 1,274 DERMA
14 13 12 16 11 12 15
9 7 9 7 8
NEURO 1,093 NEURO
20 15 11 17 10 8 10 8 14
4 4 5 GYNAEC
GYNAEC. 902
20 16 15 19 16 18 16 15 18
13 13 12
UROLOGY 380 URO
22 17 21 30 29
15 9 9 12 9 8 OPHTHAL
1
OPHTHAL 339
Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct

IQVIA TSA & SSA Dataset Oct'23 2

Therapy sorted on Month
 Top Companies #1-10 Market Share Trend
9

Val Oct'23 MS Oct'23

8 SUN* 1,429 7.53

(ABBOTT*) 1,158 6.10

7 CIPLA 999 5.26

MANKIND 869 4.58
(ALKEM*) 816 4.30
6
(MACLEODS) 684 3.60
INTAS* 663 3.49
5
(ARISTO*) 624 3.29
(LUPIN) 624 3.29
4 TORRENT 622 3.28

2
Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23

• Sun*, Cipla, Mankind, Intas* & Torrent have shown improvement in MS for Oct'23 as compared to Sep'23
• Abbott*, Alkem*, Macleods, Aristo* & Lupin reflected dip in MS for Oct'23 as compared to Sep'23

IQVIA TSA & SSA Dataset Oct'23 3

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

SUN* 1,429 17 100 SUN* 1,213 16 99

ABBOTT* 1,158 17 101 ABBOTT* 996 18 102
CIPLA 999 10 94 CIPLA 848 11 96
MANKIND 869 18 101 MANKIND 788 18 102
Month

Month
ALKEM* 816 17 100 ALKEM* 715 18 101
MACLEODS 684 22 104 MACLEODS 607 21 104
INTAS* 663 21 104 ARISTO* 565 28 110
ARISTO* 624 28 110 TORRENT 549 16 100
LUPIN 624 11 96 INTAS* 540 19 103
16 100 LUPIN 534 11 96
TORRENT 622

SUN* 16,282 11 100 SUN* 13,832 10 99

ABBOTT* 13,084 11 100 ABBOTT* 11,192 12 100
CIPLA 11,331 12 100 CIPLA 9,573 12 101
MANKIND 9,324 15 103 MANKIND 8,411 15 104
MAT

MAT
ALKEM* 8,596 14 102 ALKEM* 7,458 13 102
INTAS* 7,371 15 103 TORRENT 6,321 11 100
LUPIN 7,238 8 97 MACLEODS 6,281 16 104
TORRENT 7,176 12 100 LUPIN 6,174 7 97
MACLEODS 7,087 16 104 INTAS* 6,004 14 103
ARISTO* 6,280 16 104 ARISTO* 5,688 15 104

• TSA : Aristo* has posted highest growth followed by Macleods on Month level, while on MAT level, Aristo* & Macleods are fastest growing

• SSA : Aristo* has posted highest growth followed by Macleods on Month level, while on MAT level, Macleods has reflected the highest growth

IQVIA TSA & SSA Dataset Oct’23

4
 Top Companies #11-20 Market Share Trend
3.0

2.8
Val Oct'23 MS Oct'23
2.6 (DRL) 526 2.77

2.4 (ZYDUS*) 525 2.77

GSK* 463 2.44
2.2
GLENMARK 397 2.09
2.0 (IPCA) 389 2.05

1.8 EMCURE* 389 2.05

USV 354 1.87
1.6
(MICRO*) 314 1.65
1.4 SANOFI* 307 1.62

1.2 ALEMBIC 288 1.52

1.0

0.8

0.6
Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23

• GSK*, Glenmark, Emcure*, USV, Sanofi* & Alembic have shown improvement in MS for Oct'23 as compared to Sep'23
• DRL, Zydus*, IPCA & Micro* reflected dip in MS for Oct'23 as compared to Sep'23
.

IQVIA TSA & SSA Dataset Oct'23 5

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

DRL 459 16 100

DRL 526 13 97
ZYDUS* 431 13 97
ZYDUS* 525 13 97
GSK* 374 6 91
GSK* 463 8 93
GLENMARK 354 19 102
GLENMARK 397 17 101
Month

Month
IPCA 339 24 107
IPCA 389 24 106
EMCURE* 323 18 102
EMCURE* 389 18 101
USV 318 12 97
USV 354 12 96
MICRO * 270 10 95
MICRO * 314 11 95
ALEMBIC 260 14 98
SANOFI* 307 18 101
SANOFI* 232 13 97
ALEMBIC 288 14 98

DRL 6,087 8 97 DRL 5,242 9 98

ZYDUS* 6,062 10 98 ZYDUS* 4,927 9 98
GSK* 5,204 7 96 GSK* 4,215 7 97
GLENMARK 4,281 12 100 GLENMARK 3,783 13 101
MAT

11 99

MAT
EMCURE* 4,252 10 98 USV 3,628
IPCA 4,088 14 102 IPCA 3,524 13 102
USV 4,068 11 99 EMCURE* 3,518 11 100
MICRO * 3,458 7 96 MICRO * 2,966 9 98
SANOFI* 3,400 6 95 ALEMBIC 2,850 11 100
PFIZER* 3,270 2 91 SANOFI* 2,574 3 93

• TSA : IPCA has posted the highest growth on month level, and for MAT, IPCA followed by Glenmark posted highest growth

• SSA : IPCA has posted the highest growth on month level and for MAT, IPCA & Glenmark have reflected highest growth

IQVIA TSA & SSA Dataset Oct’23

6
 Top Companies #21-30 Market Share Trend
1.7
Val Oct'23 MS Oct'23
1.6 284 1.50
PFIZER*
1.5 FDC 209 1.10

(ERIS*) 189 0.99

1.4
(JB PHARMA*) 185 0.97
1.3
(HIMALAYA) 152 0.80
1.2 CADILA 138 0.73

1.1 AJANTA 134 0.71

LA RENON 126 0.66

1.0
(FRANCO) 120 0.63
0.9 118 0.62
INDOCO*
0.8

0.7

0.6

0.5
Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23

• Pfizer*, FDC, Cadila & Ajanta have shown improvement in MS for Oct'23 as compared to Sep’23
• La Renon & Indoco* have maintained MS in the month of Oct’23
• Eris*, JB Pharma*, Himalaya & Franco have reflected dip in MS for Oct'23 as compared to Sep'23

IQVIA TSA & SSA Dataset Oct'23 7

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

PFIZER* 284 6 91 PFIZER* 228 9 94

FDC 209 21 104 FDC 191 20 103
ERIS* 189 13 97 ERIS* 164 13 97
JB PHARMA* 185 19 102 JB PHARMA* 163 19 102
Month

Month
HIMALAYA 152 20 103 HIMALAYA 135 20 103
CADILA 138 14 98 AJANTA 119 14 98
AJANTA 134 14 98 CADILA 115 16 100
LA RENON 126 27 109 FRANCO 111 4 89
FRANCO 120 5 90 INDOCO* 107 16 100
16 99 BLUE CROSS 107 21 104
INDOCO* 118

ALEMBIC 3,176 PFIZER* 2,557 3 93

11 100
2,219 FDC 2,038 15 104
FDC 15 103
ERIS* 2,214 ERIS* 1,921 9 98
9 97
JB PHARMA* 2,169 JB PHARMA* 1,906 18 106
18 106
MAT

6 95

MAT
HIMALAYA 1,705 HIMALAYA 1,520
7 96
1,595 AJANTA 1,409 14 102
AJANTA 15 103
CADILA 1,582 FRANCO 1,344 7 97
9 97
FRANCO 1,446 CADILA 1,299 9 98
7 96
LA RENON 1,402 INDOCO* 1,168 4 94
24 111
INDOCO* 1,293 BLUE CROSS 1,147 9 98
4 94

• TSA: La Renon has posted the highest growth for the month followed by FDC and for MAT, La Renon has posted highest growth followed by JB Pharma*
• SSA: Blue cross has posted highest growth for the Month and for MAT, JB Pharma* has reflected highest growth followed by FDC

IQVIA TSA & SSA Dataset Oct’23

8
 Top Companies #31-40 Market Share Trend
0.64 Val Oct'23 MS Oct'23
0.62 HETERO* 118 0.62
0.60 BLUE CROSS 117 0.62
0.58 (CORONA) 110 0.58

0.56 P&G HLTH 102 0.54

0.54 SYSTOPIC 95 0.50

0.52 (MEDLEY) 89 0.47

WIN MEDICARE 87 0.46

0.50
H&H 81 0.43
0.48
FOURRTS 81 0.43
0.46
(APEX) 75 0.40
0.44
0.42
0.40
0.38
0.36
Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23

• Hetero*, Blue Cross, Systopic, Win Medicare, H&H & Fourrts have shown improvement in MS for Oct'23 as compared to Sep’23
• P&G Hlth has maintained MS in the month of Oct’23
• Corona, Medley & Apex reflected dip in MS for Oct'23 as compared to Sep'23

IQVIA TSA & SSA Dataset Mar’’23 9

 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

HETERO* 118 20 103 LA RENON 101 23 106

BLUE CROSS 117 21 103 HETERO* 93 17 101
CORONA 110 23 106 P&G HLTH 93 9 93
P&G HLTH 102 9 93 CORONA 93 22 105
Month

Month
SYSTOPIC 95 17 101 SYSTOPIC 84 16 100
MEDLEY 89 19 102 MEDLEY 83 19 102
WIN MEDICARE 87 17 101 WIN MEDICARE 77 18 102
H&H 81 10 94 H&H 70 8 93
FOURRTS 81 19 102 FOURRTS 69 18 102
APEX 75 13 97 APEX 67 13 97

BLUE CROSS 1,257 9 98 LA RENON 1,137 24 111

CORONA 1,233 20 108 P&G HLTH 1,084 5 95
HETERO* 1,207 21 109 CORONA 1,036 20 108
P&G HLTH 1,192 6 95 HETERO* 972 21 109
MAT

MAT
SYSTOPIC 1,054 10 99 MEDLEY 953 95
MEDLEY 1,018 5 94 SYSTOPIC 939 9 98
WIN MEDICARE 943 11 100 WIN MEDICARE 822 12 101
H&H 902 5 95 H&H 778 4 93
FOURRTS 882 13 102 FOURRTS 759 12 101
APEX 828 5 94 APEX 733 5 94

• TSA: Corona shows the highest growth at month level, while for MAT, Hetero* has posted highest growth followed by Corona
• SSA: La Renon shows the highest growth at month level, while for MAT, La Renon has posted highest growth followed by Hetero*

IQVIA TSA & SSA Dataset Oct’23

10
 Top Companies #41-50 Market Share Trend
0.42
0.41
0.40 Val Oct'23 MS Oct'23
0.39 JANSSEN 73 0.39
0.38
0.37
(BHARAT SERUM) 71 0.37

0.36 (MEYER) 70 0.37

0.35 (WALLACE) 67 0.35
0.34
0.33 RAPTAKOS 64 0.34
0.32 SAMARTH 63 0.33
0.31
ASTRA 61 0.32
0.30
0.29 BOEHRINGER 60 0.32
0.28 CENTAUR 59 0.31
0.27
0.26
MSD* 58 0.31

0.25
0.24
0.23
0.22
0.21
Oct’22 Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23

• Janssen, Samarth, Astra, Boehringer, Centaur & MSD* have shown improvement in MS for Oct'23 as compared to Sep’23
• Raptakos has maintained MS in the month of Oct’23
• Bharat Serum*, Meyer & Wallace reflected dip in MS for Oct'23 as compared to Sep'23

IQVIA TSA & SSA Dataset Oct'23 11

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

14 WALLACE 60 10 95
JANSSEN 73 98
18 MEYER 60 16 100
BHARAT SERUM 71 102
16 CENTAUR 56 13 97
MEYER 70 100
10 RAPTAKOS 55 10 95
WALLACE 67 95
Month

Month
14 BOEHRINGER 52 14 98
RAPTAKOS 64 98
33 BHARAT SERUM 51 18 101
SAMARTH 63 114
26 JANSSEN 46 -2 85
ASTRA 61 108
8 PHARMED 45 15 99
BOEHRINGER 60 93
13 DABUR 43 15 99
CENTAUR 59 97
1 NOVARTIS* 43 -16 73
MSD* 58 87

MEYER 823 12 100 WALLACE 726 10 99

BHARAT SERUM 821 1 91 MEYER 704 12 101
JANSSEN 811 3 92 RAPTAKOS 642 8 97
WALLACE 811 10 99 BOEHRINGER 601 -4 86
MAT

-1

MAT
MSD* 739 -2 88 BHARAT SERUM 588 89
RAPTAKOS 738 10 98 CENTAUR 571 6 96
NOVARTIS* 726 -3 87 JANSSEN 561 0 90
BOEHRINGER 718 -4 86 NOVARTIS* 553 -2 88
SAMARTH 679 24 112 PHARMED 539 15 104
ASTRA 657 19 107 MSD* 528 -7 84

• TSA: Samarth is the fastest growing company for the month followed by Astra and for MAT, Samarth has posted highest growth followed by Astra

• SSA: Bharat Serum shows the highest growth at month level, while for MAT, Pharmed is the fastest growing company followed by Meyer

IQVIA TSA & SSA Dataset Oct’23

12
 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

48 0.43 0.22
MONOCEF 83 DEXORANGE 42 17
18 0.39 0.21
AUGMENTIN 74 TELMA 40 17
21 0.37 0.20
FORACORT 71 MOXIKIND-CV 39 17
Top 1-10

Top 21-30
-3 0.36 0.20
MIXTARD 69 ACILOC 38 31
10 0.36 0.19
GLYCOMET-GP 69 SHELCAL 37 10
4 0.30 0.19
CLAVAM 56 PANTOP 36 33
33 0.28 0.19
LIV-52 54 MIKACIN 36 27
21 0.28 0.19
PAN 54 MANFORCE 36 5
18 0.28 0.19
CALPOL 53 MONOCEF-SB 36 46
14 0.27 0.19
THYRONORM 51 ZIFI 36 7
0.26 35 0.19
ZERODOL-SP 50 35 ROSUVAS 27
UDILIV 50 34 0.26 LEVIPIL 35 21 0.19
0.25 0.18
Top 11-20

BETADINE 48 8 ULTRACET 35 12

Top 31-40
AZITHRAL 48 10 0.25 T-BACT 33 -11 0.17
LANTUS 47 -7 0.25 ECOSPRIN-AV 33 12 0.17
DOLO 45 17 0.24 DUPHASTON 33 27 0.17
PAN-D 44 20 0.23 XONE 32 33 0.17
RYZODEG 44 27 0.23 VOLINI 32 8 0.17
BUDECORT 43 16 0.23 CILACAR 32 24 0.17
DUOLIN 43 6 0.23 TAXIM-O 32 10 0.17

• Monocef is the topmost brand with 83 Crs of sales & MS of ~0.43% for the month

• Among top 10 brands Monocef has shown highest growth followed by Liv-52 for the month

IQVIA TSA & SSA Dataset Oct’23

13
 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Oct'23 Month (in comparison to Sep'23 Month)

• Monocef has gained No 1 position at month level with a growth of 48%

• Foracort, Zerodol-SP, Udiliv, Ryzodeg & Moxikind-CV gained 1 rank to secure 3rd, 11th,12th,18th & 23rd position, respectively
• Amongst the top 10 Brands, highest growth is observed by Monocef with a growth of 48%
• Clavam, Azithral, Lantus , Dolo, Budecort & Shelcal gained 2 ranks to secure 6th,14th,15th,16th,19th & 25th position with a growth of
4%,10%,-7%, 17%, 16% & 10%

IQVIA TSA & SSA Dataset Oct’23

14
 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Oct'23 (in comparison to Sep'23), among the
Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Glenmark improved by 1 rank to reach 14th position
In the month of Oct'23 (in comparison to Sep'23), among
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Intas*, Glenmark, Emcure* & Eris* improved by 1 rank each to
reach 9th,14th, 16th & 23rd position, respectively

As per MAT Oct'23 (in comparison to MAT Sep'23), among As per MAT Oct'23 (in comparison to MAT Sep'23), among
the Top 25 companies the Top 25 companies

• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%

• IPCA & FDC improved by 2 ranks to reach 16th & 22nd position, • IPCA improved by 1 rank to reach 16th position
respectively

IQVIA TSA & SSA Dataset Oct’23

15
 Indian / MNC trends % Growth Over Same Month Last Year Indian MNC

30
26
25
21
17
20 18
16
Month Growth

15
14 14
15 13
11 9
10 9 9
11 6 7 6
4 6 3 8
5 7 2
2
0
NOV’22 DEC’22 JAN’23 FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23

Value (Rs. Crs)

Indian MNC

17,392 17,188 16,617 16,690 17,156 17,951 17,230 16,614 17,851 18,706 19,193 18,986
Share in IPM

14,406 14,239 13,804 13,856 14,141 14,863 14,266 13,776 14,829 15,577 15,999 15,815

2,985 2,948 2,813 2,834 3,015 3,089 2,964 2,839 3,022 3,130 3,194 3,171

NOV’22 DEC’22 JAN’23 FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23

• Indian companies have registered growth of 17% whereas MNC’s registered a growth of 14% for the month

IQVIA TSA & SSA Dataset Oct'23 16

 Acute / Chronic Trends
ACUTE CHRONIC
30 27
22
25
20
20 18
16 15 14
Growth (%)

15 13 13 12
11 10
13 11 9 8 9 9
10
15 5 4
5 9
0 3
0
-5
NOV’22 DEC’22 JAN’23 FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23

Gwth %
6% 22% 17% 24% 45%
Top 5 TC 4s

278 263
236
Value (Rs 207 198
Crs)

GLIMEPIRIDE+METFORM. COUGH PREP. ETHICALS AMOXY. & CLAV. SOLIDS FOOD SUPPLEMENTS CEFTRIAXONE INJECTABLS

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 69 GLENMARK 44 GSK* 50 ALKEM* 31 ARISTO* 84

LUPIN 29 DRL 29 ALKEM* 37 APEX 30 ALKEM* 41

SUN* 27 MANKIND 24 MANKIND 36 SUN* 23 MACLEODS 24

• Acute has shown growth of 18% whereas Chronic has shown growth of 14% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Oct'23 17
 Top Therapy Trends
TSA

Value_Oct'23 (Rs. Crs) % Gwth SPLY Value_Oct'23 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 115 16 J01C0G AMOXY. & CLAV. SOLIDS 236 17

C02C04 TELMISARTAN 101 11 J01D0C CEFTRIAXONE INJECTABLS 198 45

18 J01N01 MEROPENEM 135 30

Anti-Infectives
C02F06 AMLODIPINE+TELMISARTAN 88
C02G0H TELMISARTAN + HCT 74 14 J01D0Z CEFTRIAXONE+SULBACTAM 121 45
Cardiac

C10A03 ATORVASTATIN 72 -6 J01C0H AMOXY. & CLAV. LIQUIDS 120 10

B01A0E ENOXAPARIN 66 16 J01F04 AZITHROMYCIN ORAL SOLIDS 112 15

C01D0B CILNIDIPINE 60 21 J01D0L CEFIXIME ORAL SOL. 107 15

C01E03 METOPROLOL 56 0 J01D0V CEFPODOXIME SOLIDS 98 38

C02F02 ATENOLOL+AMLODIPINE 56 7 J01K05 PIPERACILLIN+TAZOBACTAM 89 33

C02F0I METOPROLOL+TELMISARTAN 55 20 J01K03 AMIKACIN 82 25

A02B0Q PANTOPR.+ DOMPERID. 137 14 A10B0Q GLIMEPIRIDE+METFORM. 278 6

A02B0R RABEPRA.+ DOMPERID. 105 11 A10C03 INTER.-ACTING+FAST ACTING 193 -1
A02B0A PANTOPRAZOLE SOLIDS 100 15 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 106 13
53

Anti Diabetic
A07L01 ORAL ELECTROLYTES 84 A10C05 LONG ACTING 90 3
A02B0B PANTOPRAZOLE INJ. 65 46 A10B0D METFORMIN + VILDAGLIPTIN 75 1
GI

A02B0S ESOMEPR.+ DOMPERID. 64 23 A10C01 FAST ACTING 74 14

A07K09 OTHERS 64 21 A10B07 METFORMIN + SITAGLIPTIN 64 28
A02B01 RANITIDINE ORAL SOLIDS 61 20 A10B0W PIOGLITAZ.+METFORM.+GLIM. 63 9
A02A05 ANTACID+ANTIFLATU.LIQ 59 33 A10B12 DAPAGLIFLOZIN 47 12
A06A07 MILK OF MAG AND COMB. 54 22 A10B0M GLICLAZIDE + METFORMIN 44 12

• In Cardiac, Cilnidipine posted 21% growth which is highest amongst top therapies
• In AI, Ceftriaxone Inj & Ceftriaxone+Salbactam posted highest growth of 45%
• In GI, Oral electrolytes subgroup posted highest growth of 53%
• In Anti diabetic, Metformin+Sitagliptin subgroup has posted highest growth of 28%
IQVIA TSA & SSA Dataset Oct’23
18
 Top Therapy Trends
TSA

Value_Oct'23 (Rs. Crs) % Gwth SPLY Value_Oct'23 (Rs. Crs) % Gwth SPLY

R05B01 COUGH PREP. ETHICALS 263 22 N02B05 PARACETAMOL ORAL SOLIDS 105 24
R03C0R FORMOTERAL+BUDESONIDE 119 22 M02A01 NSAIDS 88 10
R03B01 LEVOCETIRIZ.+MONTELU SOLD 117 8 M01A0G PARACE.+ACECLOF.+SERRAPE. 79 29
Respiratory

R05B05 LEVOSALBUTAMOL & COMB. 116 32 M05C02 CALCITRIOL COMB. 77 6

Pain
R05A02 COLD PREP. LIQUIDS 97 7 N02B07 PARACETAMOL INJECTIONS 61 32
R05B07 CHLORPHNMN+DEXTROMETHRPHN 77 32 N02B06 PARACETAMOL ORAL LIQUIDS 56 5
R05A01 COLD PREP. SOLIDS 58 15 N02B0K PARACETAMOL + TRAMADOL 47 12
R03C02 BUDESONIDE 55 19 M01A0U ACECLOFENAC + PARACETAMOL 47 15
R03C0S IPRATROPIUM + LEVOSALBU. 52 8 M05B0C COLLAGEN COMB 46 23
R03B02 MONTELUKAST+FEXOFENADINE 38 18 M01A03 DICLOFENAC INJECTABLES 38 14

V06E01 FOOD SUPPLEMENTS 207 24 D02A01 EMOLLIENTS,PROTECTIVES 140 20

A11F02 MECOBALAMIN COMB. 109 19 D01C03 ITRACONAZOLE 89 -5
A12A04 CALCIUM + COLECALCI. SOLI. 107 15 D11A09 OTH.DERMATOLOGICAL PREP. 59 19
V06C01 INFANT FORMULAS 102 26 D06A08 MUPIROCIN 42 -10

Derma
A11C02 PLAIN VIT.D 91 24 D01A02 LULICONAZOLE 41 -2
VMN

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 77 17 D02B01 SUNSCREENS 37 33

A12A01 CALCIUM ORAL SOLIDS 49 17 D16A0D OTH HAIR CARE PREPS. 31 23
A11A05 OTH. MULTIVIT.-MIN. LIQUIDS 48 25 D07D0C CLOBET+MICONAZOL+NEOMYCIN 30 9
A15A01 APPETITE STIMULANTS 48 14 D02C07 HYDROQU.+TRETI.+MOMETA. 27 -7
V06E05 ADULT WELLNESS 41 2 D02E01 MINOXIDIL 23 1

• In Respiratory therapy, Chlorphnmn +Dextromethrphn and Levosalbutamol & Comb. posted highest growth of 32%
• In Pain market, paracetamol oral solids, liquids & inj contributed ~ 222 Crs of sales with 24%, 5% & 32% growth, respectively
• In VMN, food supplements is the top contributing subgroup with 207 Cr of sales posted growth of 24%
• Emollients protectives registered highest sales of 140 Cr in derma market with 20% growth while the highest growth of 33% is observed in Sunscreens

IQVIA TSA & SSA Dataset Oct’23

19
 Top Therapy Trends
TSA

Value_Oct'23 (Rs. Crs) % Gwth SPLY Value_Oct'23 (Rs. Crs) % Gwth SPLY

N03A0T LEVETIRACETAM 92 14 B03A01 CONV.IRON SOLIDS 119 9

N06C02 ESCITALOPRAM+CLONAZEPAM 43 18 B03A02 CONV.IRON LIQUID 114 21
N03A0V GABAPENTIN + NORTRIPTYLIN 41 24 G03D04 DYDROGESTERONE 94 25
Neuro/CNS

Gynaec
N07C01 BETAHISTINE 39 19 B03A03 CONV.IRON INJ. 73 20
N07A01 PREGABALIN 29 23 G03D03 PROGESTERONE 70 7
N03A0J OXCARBAZEPINE 27 15 G03G06 HUMAN MENOPAUSAL GONADOTROP. 37 44
N07A02 PREGABALIN+MECOBALAMIN 25 5 G02C01 OTHER GYNAECO.PREP. 34 22
N03A0I NORTRIPTYLINE+PREGABALIN 25 14 G03K02 MIFEPRISTONE+MISOPROSTOL 30 2
N03A04 SODIUM VALPROATE ORAL SOLIDS 23 -6 G03G05 HUMAN CHORIONIC GONADOTROP. 27 7
N03A0D CLONAZEPAM 21 10 G03D02 NORETHISTERONE 26 9

V03D04 SILDENAFIL 43 0 S01J03 METHYL CELLULOSE/CMC 41 -3

G03J0A DUTASTERIDE + TAMSULOSIN 35 18 S02A01 OTOLOGICALS 25 6
G03J0G DUTASTERIDE + SILODOSIN 33 33 S01A0A MOXIFLOXACIN 19 4
G04B09 OTH. UROLOGICAL PREP. 31 20 S01J07 HYALURONIC ACID 16 29

Ophthal
Urology

G03J03 TAMSULOSIN 24 20 S01J0A MACROGOL+PROPYL.GLY&COMB 15 22

G04B01 URINARY ALKALISERS 21 25 S01H06 NEPAFENAC 12 2
G03J0E SILODOSIN 21 21 S01P04 ANTI-OXIDANTS-OPHTHAL 12 5
V03D05 TADALAFIL 18 26 S01G0A BRIMONIDINE + TIMOLOL 11 7
G04B0D ALPHA KETOANALOGUE 16 7 S01J04 HPMC 10 2
G04B02 FLAVOXATE 14 19 S01P07 RANIBIZUMAB 8 96

• In Neuro therapy, Levetiracetam is the top contributing subgroup with 92 Cr of sales posted growth of 14%
• In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~306 Cr of sales to the entire therapy
• In Urology therapy, Dutasteride+Silodosin posted highest growth of 33%
• Methyl Cellulose registered highest sales of 41 Cr in ophthal therapy with -3% growth while the highest growth of 96% is observed in Ranibizumab

IQVIA TSA & SSA Dataset Oct’23

20
Key changes
PTR Changes (Top 50 brands) New Introduction

➢ Total number of SKUs with PTR changes in Oct'23 are 2968. ➢ 1211 new packs were Introduced in Oct'23
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Mixtard, Glycomet-GP, Foracort, Monocef,
Clavam, Liv-52, Betadine, Ryzodeg, Duolin, Azithral, Dolo, Levipil,
Duphaston, Ecosprin-AV, Mikacin & Pantop

New Lab & Corporate Brand Transfer

➢ Corporates & Labs were introduced in Oct'23 dataset are mentioned Following brands transfers registered in Oct’23 are :
below :
➢ Disperyme has transferred from Aksigen to Sun Pharma
• Microgene Diagno.
• Nexina Life Scien. ➢ Disperyme-CD has transferred from Aksigen to Sun Pharma
• Vissco Healthcare ➢ Phlogam has transferred from Aksigen to Sun Pharma
➢ Tidilan has transferred from Juggat Pharma to Bharat Serum

IQVIA TSA & SSA Dataset Oct'23 21

THANK YOU

22